Case file — 6D5EA57A
The idea
“Specialty pharmacy prior authorization is fundamentally different from primary care PA: specialty drugs cost $5K-50K/month, require clinical justification letters citing specific lab values, fail-first documentation proving cheaper drugs were tried, and gene therapy protocols that don't fit any standard form. Specialty pharmacy PA teams spend 30-60 minutes per patient on these requests and 10,000+ specialty pharmacies have dedicated PA staff. CoverMyMeds (McKesson) handles primary care drugs well but isn't built for specialty workflows. We build PA automation specifically for specialty pharmacy: ingest patient demographics, diagnosis codes, lab values, and prescription history, auto-generate clinical justification letters in the format each payer requires, track status and appeal automatically. Price: $3K-10K/month per pharmacy.”
The panel
No named competitors with funding data appear in your live search results. The search returned generic PA guides (MediAppeal, DenialCrusher) and Reddit friction signals—no actual SaaS vendors competing in specialty pharmacy PA automation. That's a red flag: either the market is genuinely uncontested, or solutions exist but aren't discoverable via standard search. CoverMyMeds dominates primary care; whether they've genuinely ignored specialty workflows or are quietly building it matters before you invest heavily. The market signal is real—Reddit shows staff drowning in PA burden and specialty pharmacy friction. But you have zero traction data, no customer interviews, and no proof that $3K-10K/month pricing sticks with 10,000 targets. Your TAM math assumes all specialty pharmacies have dedicated PA teams; many don't. Genuine strength: specialty drug volumes are rising (oncology, gene therapy, biologics), and payer requirements are fragmenting faster than primary care, creating genuine workflow pain. But that pain alone doesn't validate willingness to switch from manual processes or existing tools.
You're underestimating payer integration complexity. Each insurer's PA system has proprietary APIs, submission formats, and real-time validation rules that change quarterly. Building connectors for 50+ major payers isn't a feature—it's permanent infrastructure debt. You'll spend 40% of engineering capacity on payer maintenance forever, not on product. Buy-versus-build trap: clinical letter generation. You'll want to license or partner with established clinical content vendors rather than build from scratch. Payers scrutinize letter provenance; homegrown templates create liability and rejection risk. No moat here yet. The barrier is operational—relationships with payers and pharmacies—not technical. A determined competitor (or McKesson itself) replicates this in 18 months once they see traction. What works: specialty pharmacy workflows are genuinely messy and underserved. Your problem diagnosis is sharp. The $3K-10K/month pricing against 30-60 min/patient savings is defensible math. Start narrow—one payer, one therapy area (oncology)—before attempting horizontal specialty coverage.
Your CAC/LTV problem: specialty pharmacies are fragmented, cost-conscious, and already embedded with CoverMyMeds or manual workflows. Displacing entrenched software requires either massive sales effort (high CAC) or proving ROI so tight that a pharmacy can't ignore it. You're betting on $3-10K/month stickiness, but pharmacies will demand proof-of-concept on their highest-friction cases first—meaning freemium or pilot pricing that erodes unit economics before you're at scale. Your pricing assumption that's probably wrong: you're anchoring to $3-10K/month based on "dedicated PA staff cost," but pharmacies don't hire one FTE per location—they centralize PA teams across 5-50 locations. Your buyer is a regional or national chain, not 10,000 individual pharmacies. Deal size may be 2-3x higher, but sales cycle and implementation complexity scale with it. Runway math: you have zero revenue and this is pre-product. If you're bootstrapped, you'll hit the wall in 6-12 months. If VC-backed with $1M, you have ~18 months to land 3-5 paying pilots that prove the model before unit economics matter. One thing working for you: specialty drug PA is genuinely high-friction and payer requirements change frequently. Automation here solves a real, repeatable problem with measurable time savings (30-60 min/patient). That's defensible if you can embed deep enough into payer requirements.
Timing verdict: Late, but with a narrow opening. The specialty PA problem is real and CoverMyMeds has ignored it for years—that's your signal that the market exists. But you're entering as automation-first in a space where payers are actively tightening requirements (gene therapy protocols, fail-first mandates, real-time lab verification). You're 3–4 years behind where you should have launched, and the next 18 months will determine if payers lock down API access to their PA systems or if they keep this fragmented. If they standardize, your moat evaporates. The macro trend that matters most: payer consolidation and real-time verification mandates. UnitedHealth, CVS Caremark, and Humana are pushing pharmacies toward direct EHR integration and real-time eligibility checks. This either becomes your distribution channel (payers embed your tool) or makes your tool obsolete (they build it themselves). Right now it's unclear which way it tips. Window status: Open but narrowing fast. Specialty pharmacies are desperate enough to pay, but payers are moving toward automation at their end. You have 18–24 months before the market fragments into payer-specific solutions. One genuine tailwind: CMS is mandating prior auth reduction metrics by 2027. Pharmacies that can prove faster, documented PA workflows gain competitive advantage with PBMs. That's your sales hook today.
Cause of death
Payer Integration Is Not a Feature — It's a Permanent Tax
The tech panel nailed this: each insurer has proprietary APIs, submission formats, and real-time validation rules that change quarterly. You'll spend 40% of engineering capacity on payer connector maintenance forever. This isn't a build-once problem — it's an ongoing infrastructure burden that scales linearly with payer coverage. CoverMyMeds can absorb this cost across millions of primary care transactions. You'll be absorbing it across a few hundred specialty pharmacy customers. The unit economics of maintenance alone could make this business structurally unprofitable until you hit significant scale, and you have no clear path to that scale yet.
Your Buyer Isn't Who You Think It Is
The finance panel flagged something critical: specialty pharmacies don't operate PA teams per-location. They centralize PA staff across 5-50 locations, often at regional or national chain level. Your 10,000-pharmacy TAM collapses into maybe 500-1,500 actual buying entities — corporate PA operations at chains like BioScrip, Option Care Health, PharMerica, or the specialty arms of CVS and Walgreens. That means longer enterprise sales cycles, procurement committees, IT security reviews, and integration requirements with their existing pharmacy management systems. Your $3K-$10K/month pricing per pharmacy might actually need to be $15K-$50K/month per enterprise — which is a different sales motion, different funding requirement, and different product entirely.
The 18-Month Window Is Real and You're Starting From Zero
The timing panel identified a narrowing window: payers like UnitedHealth and CVS Caremark are pushing toward direct EHR integration and real-time eligibility checks. If payers build their own specialty PA automation (or lock down API access to force pharmacies onto their portals), your tool becomes redundant. You have 18-24 months before this market fragments into payer-specific solutions — and you haven't written a line of code. Even with aggressive execution, you're looking at 6-9 months to MVP, 3-6 months to first pilot, and another 6 months to prove ROI. That's your entire window consumed by just getting to product-market fit.
⚠ Blind spot
Clinical liability. When your auto-generated justification letter cites a lab value that's stale, misinterpreted, or pulled from the wrong encounter — and a payer denies coverage for a $40,000/month oncology drug — the pharmacy doesn't blame the payer. They blame your software. The tech panel mentioned that payers scrutinize letter provenance and that homegrown templates create rejection risk, but it's worse than that: you're inserting yourself into a clinical documentation chain where errors have direct patient care consequences. One high-profile denial tied to your auto-generated letter, and your reputation in a small, relationship-driven market is destroyed. Specialty pharmacy directors talk to each other. You need clinical pharmacist review built into the workflow — which partially negates the automation value proposition and adds cost to every transaction.
What would need to be true
At least one major payer (UHC, Aetna, or Cigna) must maintain open or semi-open API access to their specialty PA submission systems through 2028 — if payers lock down to proprietary portals, your automation layer has no surface to attach to.
Specialty pharmacy PA teams must be willing to trust software-generated clinical justification letters without requiring full pharmacist review of every output — if clinical liability concerns force manual review of every letter, your time savings collapse from 60% to 15%, and your ROI story dies.
CoverMyMeds (McKesson) must not ship a specialty pharmacy PA module within 18 months of your launch — they have the payer relationships, the pharmacy install base, and the engineering resources to build this faster than you if they decide to prioritize it. Your survival depends on them continuing to ignore this segment long enough for you to embed.
Recommended intervention
Don't build a horizontal specialty PA platform. Build a payer-specific oncology PA engine for UnitedHealthcare first. UHC is the largest commercial payer, oncology is the highest-volume specialty category, and UHC's PA requirements for oncology drugs (NCCN guideline citations, specific lab thresholds, fail-first documentation for biosimilars) are well-documented and stable enough to automate reliably. Go to 5 oncology-focused specialty pharmacies that process 200+ UHC oncology PAs per month, offer a 90-day free pilot on UHC cases only, and prove that you cut PA processing time by 60%+ with equal or better approval rates. That gives you: (a) a tight enough scope to build in 4-5 months, (b) measurable ROI data for a single payer that you can use to raise a seed round, (c) a wedge into the exact buyer (oncology specialty pharmacy) that has the most acute pain and the highest drug costs to justify your pricing. Then expand payer by payer, therapy area by therapy area — each one a new revenue unlock, not a new product.
Intervention unlocking
5seconds
No account needed. One email, no follow-ups.
Want your idea examined? Free triage or full panel →